Steve Ruston PhD – Chief Executive Officer
Dr. Ruston completed a PhD in synthetic organic chemistry at the University of Leeds.
His career path in Pharma & the Fine Chemicals sectors has provided wide-ranging roles in pharmaceutical R&D, chemical manufacturing & site operations with key roles in Smith Kline, Courtaulds, GlaxoWellcome & Pfizer in the UK, USA & Latin America.
He contributed to the teams responsible for the development and commercial success of Tagamet, Zantac, Imigran and Viagra and was responsible for the design, commissioning and operation of R&D laboratory and chemistry pilot plant facilities with a capital value in excess of £300m.
As CEO he led the growth and development of a UK-based biotechnology company from its university spinout stage through to a successful sale to an international Pharmaceutical company.
Dr. Ruston’s management responsibilities include all aspects of running a business including direction of scientific teams and projects, finance, legal, human resources and operations.
Lloyd Czaplewski PhD – Chief Scientific Officer
Dr. Czaplewski was awarded a PhD in Molecular Genetics from the University of Glasgow and followed this with postdoctoral research studies at the University of Leeds.
He then embarked on a career path of the highest scientific and technical calibre working in the biotechnology sector and key positions included Head of Biology at British Biotech, UK and Vice President R&D, Prolysis and Biota (Europe).
His R&D experience has been gained in multiple therapeutic areas from fundamental research to clinical evaluation and in particular he is recognized as a leading expert in the discovery, development and use of antibacterial medicines.
Dr. Czaplewski has published numerous scientific papers in leading journals as well as filing multiple patent applications.
He is working with a number of academic technology transfer groups and consults for the Wellcome Trust and has a successful track record working at Board level to assist in corporate fundraising, commercial deal discussions and patent assignments.
Sarah Guest MSc – Operations & Project Manager
Sarah Guest gained her BSc in Biochemistry from Kent University and subsequently her MSc in Epidemiology from the London School of Hygiene and Tropical Medicine.
During her 19-year career at Pfizer, Sarah progressed to Director within Global Project Management. She has extensive experience across all phases of drug development and multiple therapeutic areas, and played a key role in the successful registration and approval of Relpax TM. Biotechnology experience has been gained at ProtAffin Biotechnologie AG, an Austrian based company, where she was involved in the execution of the company’s first clinical study.
Eliot Forster PhD MBA – Pharmaceutical Development Advisor
Eliot Forster has almost 25 years experience in the biotechnology industry and joined Immunocore as Chief Executive Officer in January 2015. He previously served as CEO of Creabilis since 2010 and prior to that was CEO of US biotechnology company, Solace Pharmaceuticals Inc. Other previous roles include Head of EU Development and Operations for the EU and Asia at Pfizer, responsible for drug development activities across multiple geographies and brought several drugs to market, and Clinical Research Manager at GlaxoSmithKline. Dr Forster is currently Chairman of the MedCity project that aims to grow a world-leading life sciences cluster in London and the greater south east. He holds a PhD in neurophysiology from Liverpool University and an MBA from Henley Management College.
Marie Lossky PhD – Intellectual Property Advisor
Dr. Lossky obtained her AB in Biochemistry and Molecular Biology from Harvard University and her PhD in Biochemistry from Imperial College London.
After postdoctoral studies at Brandeis University, Dr. Lossky joined the technology transfer group at Massachusetts General Hospital and later Partners HealthCare. She and her team were in charge of a wide range of technologies giving rise to complex intellectual property issues, licenses, and R&D alliances. Durasul (Zimmer), Byetta (AstraZeneca), and Victoza (Novo Nordisk) are some of the major products to emerge from these activities.
Dr. Lossky left Partners HealthCare to join the management team at Solace Pharmaceuticals. Subsequently she passed the Patent Bar and started an intellectual property consulting firm, Essex IP LLC. In this capacity she advises both early- and later-stage biomedical companies on intellectual property and licensing issues, with a special focus on aligning intellectual property strategy to business objectives
Peter J Hamlyn, Consultant Spinal Surgeon
Mr. Hamlyn graduated from UCL Medical School in 1982 and became a Fellow of the Royal College of Surgeons in 1986. He was awarded the Roger’s Prize for medical research in 1993 and became a Fellow of the Institute of Sports Medicine in 1996.
Current positions include Director of Education, Institute of Sports Medicine and Health at UCL, Honorary Consultant Neurosurgeon to University College London Hospital, Vice Chairman, Brain and Spine Foundation, Chairman, Foundation for Human Potential, Trustee of the Grand Prix Mechanics Trust and Directorships at the Broadgate Spine & Joint Clinic and The Spine Surgery London.
In 2000 he chaired the Ministerial Working Group on Medicine and Safety in Sport. From July 2004 – July 2005 he was a Member of the 2012 London Olympic Bid Advisory Panel. Research Activity includes a period as Convener of Queen Mary University of London Spinal Cord Injury Group – a £750,000 funded research program & a grant from the Migraine trust.
Author of one neurosurgical text book (2000) and multiple publications in peer reviewed journals and presentations to learned societies.
He was a member of the International Symposia on Concussion in Sport: Prague and Zurich and is the convener of the National Initiative in Concussion in collaboration with the RFU and Premiere League football.
His clinical activity includes in the region of 2,500 consultations and 300 operations, (almost exclusively spinal), per year. He routinely works in elite level sport including: Premiere League Rugby and Football, Horse Racing, Tennis, PGA golf, Boxing, Motor Sports including Formula 1, and NFL (London).
Alan A Jordan PhD DC – Director
Dr Jordan qualified as a Chiropractor at the Canadian Memorial Chiropractic College in 1979. He completed a doctorate in medical research at the Faculty of Medicine, Royal National University Hospital, Copenhagen in 1996.
He worked as an Associate Professor & course coordinator, Faculty of Sports Medicine & Clinical Biomechanics, University of Southern Denmark 1998-2003. He was a Founder of the Spine Centre, University Hospital Ringe, Denmark, where much of the Modic related research was carried out.
He has published extensively in peer-reviewed journals and co-authored two books on spinal pain and was awarded Scandinavian researcher of the year in 1997 by The Danish Society of Musculoskeletal Disease.
Charity work includes the Danish Association for Arthritis and several patient associations. He is currently a Director of the Broadgate Spine & Joint Clinic, London.
Hanne Albert PhD
After qualifying as a physiotherapist in Copenhagen, Dr Albert was awarded a Masters of Public Health for her research work in the pelvic pain sphere from the Univesity of Gothenburg Sweden, 2000. She was thereafter employed as a PhD candidate at the Spine Centre, University of Southern Denmark. She received her PhD at the Faculty of Health Sciences, University of Southern Denmark in 2004.
During her research on patients with disc herniations, Dr Albert discovered that approximately 50% of patients developed Modic changes (bone oedema) within a year; she was the first to describe the connection between a previous disc herniation and new Modic changes in the adjacent vertebra. She was awarded the prize for the best scientific presentation at the European Spine conference in 2005 for this work.
Dr Albert has published numerous groundbreaking studies in this field and was the lead scientist in the renowned randomised clinical trial which demonstrated that an extended course of oral antibiotics resulted in significant improvement to patients suffering with chronic low back pain and Modic changes.
She has been awarded the prestigious annual Pain Research Prize from the German Pain Society (2017).
Dr Albert continued working at the Spine Centre as a Senior Researcher and Associate Professor until 2013, and is currently the Medical Director at the Modic Clinic, Odense, Denmark.
Professor Claus Manniche PhD MD
Prof. Manniche graduated from the University of Copenhagen Medical School in 1982 and was granted permission to practise medicine in 1985. His work subsequently led to becoming a Specialist Doctor in Rheumatology in 1994 and in 1998 was appointed as Chief Consultant, Professor, at the Spine Centre of Southern Denmark.
He has played a key role in several influential committees and research groups including the Danish Rheumatology Society and the Copenhagen Back Research Association (COBRA). From 2007 to 2012 he was appointed by the Danish Minister of Health as a member of a specialist committee investigating the prevention of back pain.
He has multiple publications in peer-reviewed journals and presentations to learned societies, has contributed to the discovery of Modic changes, and was one of the lead authors of the ground-breaking work that demonstrated that treatment with an extended course of oral antibiotics resulted in significant improvement to the Chronic Lower Back Pain patients’ pain levels and general physical condition.